[go: up one dir, main page]

FR2866569B1 - Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap - Google Patents

Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap

Info

Publication number
FR2866569B1
FR2866569B1 FR0401721A FR0401721A FR2866569B1 FR 2866569 B1 FR2866569 B1 FR 2866569B1 FR 0401721 A FR0401721 A FR 0401721A FR 0401721 A FR0401721 A FR 0401721A FR 2866569 B1 FR2866569 B1 FR 2866569B1
Authority
FR
France
Prior art keywords
receptor
type
interleukine
metronidazole
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0401721A
Other languages
English (en)
Other versions
FR2866569A1 (fr
Inventor
Fabrizio Folfi
Irina Safonova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0401721A priority Critical patent/FR2866569B1/fr
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to KR1020067016588A priority patent/KR20060124707A/ko
Priority to JP2006553618A priority patent/JP2007523133A/ja
Priority to EP05729371A priority patent/EP1718296A2/fr
Priority to PCT/FR2005/000370 priority patent/WO2005089750A2/fr
Priority to AU2005224123A priority patent/AU2005224123A1/en
Priority to CA002553932A priority patent/CA2553932A1/fr
Priority to RU2006133534/15A priority patent/RU2006133534A/ru
Priority to US10/590,031 priority patent/US20080221189A1/en
Priority to CNA2005800055751A priority patent/CN1921852A/zh
Priority to BRPI0506550-0A priority patent/BRPI0506550A/pt
Publication of FR2866569A1 publication Critical patent/FR2866569A1/fr
Application granted granted Critical
Publication of FR2866569B1 publication Critical patent/FR2866569B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0401721A 2004-02-20 2004-02-20 Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap Expired - Fee Related FR2866569B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0401721A FR2866569B1 (fr) 2004-02-20 2004-02-20 Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap
US10/590,031 US20080221189A1 (en) 2004-02-20 2005-02-17 Use of Metronidazole For Preparing a Pharmaceutical Composition For Treating Pathologies Related to the B-Type Receptor of Interleukin 8 and/or to a Pacap Type 1 Receptor
EP05729371A EP1718296A2 (fr) 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap
PCT/FR2005/000370 WO2005089750A2 (fr) 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement des pathologies liees au recepteur de type b de l’interleukine 8 et/ou recepteur de type 1 de pacap
AU2005224123A AU2005224123A1 (en) 2004-02-20 2005-02-17 Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the B-type receptor of interleukin 8 and/or to a pacap type 1 receptor
CA002553932A CA2553932A1 (fr) 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement des pathologies liees au recepteur de type b de l'interleukine 8 et/ou recepteur de type 1 de pacap
KR1020067016588A KR20060124707A (ko) 2004-02-20 2005-02-17 인터루킨 8 의 ｂ-형 수용체 및/또는 ｐａｃａｐ 1형수용체와 관련된 병상의 치료용 약학 조성물의 제조를 위한메트로니다졸의 용도
JP2006553618A JP2007523133A (ja) 2004-02-20 2005-02-17 インターロイキン８タイプｂレセプタ及び／又はｐａｃａｐタイプ１レセプタに関連した病変治療用薬剤組成物を調製するためのメトロニダゾールの使用
CNA2005800055751A CN1921852A (zh) 2004-02-20 2005-02-17 甲硝唑在制备用于治疗与白细胞介素8的b型受体和/或pacap的1型受体相关病理学的药物组合物中的用途
BRPI0506550-0A BRPI0506550A (pt) 2004-02-20 2005-02-17 uso do metronidazol para a preparação de uma composição farmacêutica
RU2006133534/15A RU2006133534A (ru) 2004-02-20 2005-02-17 Применение метронидазола для получения фармацевтической композиции, предназначенной для лечения патологий, связанных с рецепторами интерлейкина 8 типа в и/или рецептором расар типа 1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0401721A FR2866569B1 (fr) 2004-02-20 2004-02-20 Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap

Publications (2)

Publication Number Publication Date
FR2866569A1 FR2866569A1 (fr) 2005-08-26
FR2866569B1 true FR2866569B1 (fr) 2007-08-24

Family

ID=34833946

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0401721A Expired - Fee Related FR2866569B1 (fr) 2004-02-20 2004-02-20 Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap

Country Status (11)

Country Link
US (1) US20080221189A1 (fr)
EP (1) EP1718296A2 (fr)
JP (1) JP2007523133A (fr)
KR (1) KR20060124707A (fr)
CN (1) CN1921852A (fr)
AU (1) AU2005224123A1 (fr)
BR (1) BRPI0506550A (fr)
CA (1) CA2553932A1 (fr)
FR (1) FR2866569B1 (fr)
RU (1) RU2006133534A (fr)
WO (1) WO2005089750A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961695B1 (fr) * 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US20130102572A1 (en) * 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
FR2722098B1 (fr) * 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
CA2161737C (fr) * 1995-10-30 1998-10-20 Richard J. Mackay Gel de metronidazole
GB9626513D0 (en) * 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
US6365616B1 (en) * 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
CN1304001C (zh) * 1999-07-16 2007-03-14 株式会社昭荣 含有硝基咪唑的皮肤病外用药
CA2446356C (fr) * 2001-05-09 2012-07-10 The Regents Of The University Of Michigan Compositions pour le traitement de l'acne rosacee
DE602004004399T2 (de) * 2003-06-18 2007-06-21 Galderma S.A., Cham Grün gefärbte topische pharmazeutische zusammensetzung auf der basis von metronidazol

Also Published As

Publication number Publication date
BRPI0506550A (pt) 2007-02-27
US20080221189A1 (en) 2008-09-11
CA2553932A1 (fr) 2005-09-29
WO2005089750A2 (fr) 2005-09-29
FR2866569A1 (fr) 2005-08-26
WO2005089750A3 (fr) 2006-05-04
RU2006133534A (ru) 2008-03-27
AU2005224123A1 (en) 2005-09-29
JP2007523133A (ja) 2007-08-16
CN1921852A (zh) 2007-02-28
KR20060124707A (ko) 2006-12-05
EP1718296A2 (fr) 2006-11-08

Similar Documents

Publication Publication Date Title
FR2867778B1 (fr) Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
FR2921795B1 (fr) Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
MA28722B1 (fr) Composition pharmaceutique orodispersible pour administration oromucosale ou sublinguale d'agomelatine.
FR15C0046I2 (fr) Medicaments pour le traitement ou la prevention de maladies fibrotiques
EP1838321A4 (fr) Antagonistes de cxcr4 pour le traitement de l'infection due au vih
EP2047853A4 (fr) Utilisation de stéroïde marin dans la préparation d'un médicament pour le traitement des lésions neuronales
FR2902010B1 (fr) Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
FR2876280B1 (fr) Composition cosmetique pour le soin et/ou le maquillage, resistante a l'eau, comprenant au moins un latex ou un pseudo-latex et facilement demaquillable
MA28844B1 (fr) Composition pharmaceutique comprenant de la drospirenone et de l'ethynylestradiol
FR2902325B1 (fr) Utilisation de 3h-1,2-dithiole-3-thione, d'anethole dithiomlethione, de sulforaphe, de phenethyl isothiocyanate, de 6-methyle-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie
EP1758605A4 (fr) Prouroguanyline servant d'agents therapeutiques ou diagnostiques
EP1750513A4 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
FR2792835B3 (fr) Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
FR2890304B1 (fr) Un dispositif pour mesurer la resistance a la deformation d'une cornee.
FR2866569B1 (fr) Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap
FR2872798B1 (fr) Ensemble de blisters pour dispositif d'inhalation
FR2906472B1 (fr) Solutions ioniques hypertoniques a base d'eau de mer non diluee, leur utilisation en tant que medicaments et pour la preparation de medicaments destines au traitement de la congestion nasale.
EP1726313A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose
FR2872707B1 (fr) Dispositif d'assistance circulatoire pour le coeur
EP1799849A4 (fr) Agents pour le traitement ou la prevention d'une affection allergique
FR2886151B1 (fr) Utilisation de la colchicine pour la preparation d'un medicament destine a la prevention et/ou au traitement de l'endometriose
FR2866568B1 (fr) Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter un desordre de la vascularisation cutanee
FR2862537B1 (fr) Utilisation du fepradinol pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee
FR2883180B1 (fr) Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2878160B1 (fr) Utilisation du n-acetyl-taurinate de magnesium pour la preparation de medicaments inhibiteurs de l'hypersensiblite photique

Legal Events

Date Code Title Description
CA Change of address
ST Notification of lapse

Effective date: 20081031